P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients With High PD-L1 Expression in Singapore

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.976
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy